NCT05282797View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB1 Antagonist ANEB-001 in a THC Challenge Test

PHASE2CompletedINTERVENTIONAL
Enrollment

154

Participants

Timeline

Start Date

December 15, 2021

Primary Completion Date

August 26, 2023

Study Completion Date

August 26, 2023

Conditions
Acute Cannabinoid Intoxication
Interventions
DRUG

ANEB-001

Experimental Treatment

DRUG

Placebo

Placebo comparator

Trial Locations (1)

2333

Centre for Human Drug Research (CHDR), Leiden

Sponsors
All Listed Sponsors
lead

Anebulo Pharmaceuticals

INDUSTRY

NCT05282797 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB1 Antagonist ANEB-001 in a THC Challenge Test | Biotech Hunter | Biotech Hunter